Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Buffa, Viviana ^a   Klein, Katja ^a   Fischetti, Lucia ^a   Shattock, Robin J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; TETANUS TOXOID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE MUCOSA; SUBLINGUAL GLAND; TH1 CELL; TH2 CELL; TISSUE DISTRIBUTION; VAGINA MUCOSA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, SUBLINGUAL; AIDS VACCINES; ANIMALS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV INFECTIONS; HIV-1; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIGANDS; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; TETANUS TOXOID; TOLL-LIKE RECEPTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

EID: 84871269972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050529     Document Type: Article

References (41)

1. Hankins CA, de Zalduondo BO, (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 24 Suppl 4: S70-80.
2. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444.
3. Levine MM, (2000) Immunisation against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31: 336-355.
4. Lamm ME, (1997) Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51: 311-340.
5. Chadwick S, Kriegel C, Amiji M, (2009) Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 9: 427-440.
6. Holmgren J, Czerkinsky C, (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
7. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
8. Naz RK, (2012) Female genital tract immunity: distinct immunological challenges for vaccine development. J Reprod Immunol 93: 1-8.
9. Lambrecht BN, Kool M, Willart MA, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29.
10. Lahiri A, Das P, Chakravortty D, (2008) Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26: 6777-6783.
11. Warshakoon HJ, Hood JD, Kimbrell MR, Malladi S, Wu WY, et al. (2009) Potential adjuvantic properties of innate immune stimuli. Hum Vaccin 5: 381-394.
12. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL, (2001) The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol 21: 103-120.
13. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79: 2910-2919.
14. Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, et al. (2006) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74: 694-702.
15. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, et al. (2010) Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 107: 9843-9848.
16. Steinhagen F, Kinjo T, Bode C, Klinman DM, (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
17. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. (2011) Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29: 1421-1430.
18. Arca HC, Gunbeyaz M, Senel S, (2009) Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 8: 937-953.
19. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, et al. (2010) Sublingual immunisation with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28: 5582-5590.
20. Kweon MN, (2011) Sublingual mucosa: A new vaccination route for systemic and mucosal immunity. Cytokine 54: 1-5.
21. Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, et al. (2010) Persistence of mucosal and systemic immune responses following sublingual immunisation. Vaccine 28: 4175-4180.
22. Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, et al. (2012) Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One 7 (3):: e33736.
23. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, et al. (2009) Sublingual immunisation with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 183: 7851-7859.
24. Novak N, Haberstok J, Bieber T, Allam JP, (2008) The immune privilege of the oral mucosa. Trends Mol Med 14: 191-198.
25. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L, (2011) Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 154: 336-344.
26. Staines NA, Harper N, Ward FJ, Malmstrom V, Holmdahl R, et al. (1996) Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 103: 368-375.
27. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A, (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31: 3388-3393.
28. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, et al. (2005) Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201: 1157-1167.
29. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, et al. (2007) Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 6: 835-847.
30. Wegmann F, Krashias G, Luhn K, Laamanen K, Vieira S, et al. (2011) A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS One 6: e15861.
31. Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, et al. (2010) Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 3: 57-68.
32. Black CA, Rohan LC, Cost M, Watkins SC, Draviam R, et al. (2000) Vaginal mucosa serves as an inductive site for tolerance. J Immunol 165: 5077-5083.
33. Russell MW, (2002) Immunisation for protection of the reproductive tract: a review. Am J Reprod Immunol 47: 265-268.
34. Wright PF, (2011) Inductive/effector mechanisms for humoral immunity at mucosal sites. Am J Reprod Immunol 65: 248-252.
35. Mapletoft JW, Latimer L, Babiuk LA, van Drunen Littel-van den Hurk S, (2010) Intranasal immunisation of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol 17: 23-35.
36. Mohanan D, Slutter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, et al. (2010) Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 147: 342-349.
37. Senti G, Johansen P, Kundig TM, (2009) Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 9: 537-543.
38. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE, (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14: 201-207.
39. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW, (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25: 2085-2094.
40. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM, (1995) T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 181: 713-721.
41. Reiner SL, Locksley RM, (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.